Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Michael Young who wrote (3265)	4/1/2001 1:28:07 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 52153

Bearish views without balance tick many of us off. Many (most) of us at SI-biotech are as antagonistic to crap companies as anyone in the press. It's not as though you've seen CLPA supporters here. thestreet.bomb has taken shots at the sector, without a reasonable discussion of absolute or relative valuations. For those who guffaw at "absolute" value in biotech, it's the easy thing to do. Those of us who study it make money long, regardless of whether or not the market is kind. Anybody at TSCM ready to challenge my public record? No. Do you believe that Avalon outperformed me last year? Not even close. Biotech is an easy target (no profits, often little revenue) for the deceptive and for those who want to control the fear airwaves. If someone takes justifiable and justified shots at the sector and/or a sector company, we don't object. The clearest and most accurate calls -- anywhere, February 2000 -- were made in this thread and the BVF thread. TSCM is a Johnny-come-lately opportunist crew, trying to hang on via subscription as a new darling of "gang rule" momentum traders. The smartest way to make money may be to simply wait for their mistakes, delay a little to allow the dumb flock to follow, and then strike. I am not implying that they'll make more mistakes than good calls. But, given their sector commentary to date, I am assured that they'll make some doozie mistakes. >> After all, we all want to avoid crap like CLPA. << Agreed. >> A lot of hype in biotech, so I like reading bearish viewpoints. << Me too. Some of us used to do more in the way of going after the crap companies, but death threats, cyberstalkers, etc. tend to get old. Biotech -- two decades to come -- is the sector for leverage and the creation of wealth.